Back to Rathbones Group PLC Rathbones Group PLC

IBRXIBRX
Showing 8 of 12 quarters

Position history for Rathbones Group PLCRathbones Group PLC's holdings in IMMUNITYBIO INC

Yes. Rathbones Group holds 163,220 shares of IBRX (Immunitybio), worth $1.4M, as of its Q2 2026 13F filing. It increased the position by 9,800 shares (+6.4%) from Q1 2026. Rathbones Group has held IBRX since Q3 2023, across 12 quarterly 13F filings.

Current Value

$1.4M

Current Shares

163,220

Total Value Change

+$1.2M

Total Shares Change

+89,800

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
163,220
+6.4%
$1.4M0.0%$8.76
27
2026-Q1
Decreased
153,420
-5.0%
$1.2M0.0%$7.67
0
2025-Q4
Unchanged
161,420
0.0%
$319,6110.0%$1.98
0
2025-Q3
Increased
161,420
+37.5%
$397,0930.0%$2.46
31
2025-Q2
Increased
117,420
+21.5%
$309,9880.0%$2.64
28
2025-Q1
Increased
96,620
+8.1%
$290,8260.0%$3.01
25
2024-Q4
Increased
89,420
+21.8%
$228,9150.0%$2.56
28
2024-Q3
Unchanged
73,420
0.0%
$273,1220.0%$3.72
0

Other major holders of IBRX: BlackRock, Inc., STATE STREET CORP, VANGUARD PORTFOLIO MANAGEMENT LLC, VANGUARD CAPITAL MANAGEMENT LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used